TITLE

Flawed arithmetic on drug development costs

AUTHOR(S)
Subbaraman, Nidhi
PUB. DATE
May 2011
SOURCE
Nature Biotechnology;May2011, Vol. 29 Issue 5, p381
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a study by researchers Donald W. Light and Rebecca Warburton on the median cost of developing drugs. The study which estimated median drug development cost to be as low as 59 million U.S. dollars has raised concerns. Critics argue that the researchers made the wrong assumption that clinical trial and regulatory review times are declining as well as underestimated the attrition rates and risks of drug discovery. The researchers contend that their estimate excludes the cost of discovery.
ACCESSION #
60459103

 

Related Articles

  • Economic Costs of Attrition in Clinical Trials. DOHERTY, N. J. G. // Journal of Dental Research;May1982, Vol. 61 Issue 5, p649 

    Conventional analyses of the cost-effectiveness of preventive regimens fail to account for the impact of attrition on reported costs. Using an economic model in which costs are allocated to fixed and variable components, and data from a recently completed clinical field trial, costs per...

  • $43M to Develop a Drug? An Unlikely Conclusion. Thiel, Karl // BioWorld Today;3/16/2011, Vol. 22 Issue 51, p1 

    The article discusses the cost of developing a drug. According to a study by Donald Light of the University of Medicine and Dentistry in Princeton, New Jersey, and Rebecca Warburton of the University of Victoria, the cost of drug development is about 55 million dollars, significantly lower than...

  • IMPROVING PRECLINICAL EFFICACY TESTING OF CANCER DRUGS USING PATIENT-RELEVANT MODELS. Kumari, Rajendra // Pharma Magazine;Nov/Dec2011, Vol. 7 Issue 6, p16 

    The article focuses on efforts to increase drug development efficiency and reduce attrition rates using new technologies and models such as three-dimensional multicellular systems. It states that cancer drugs entering clinical trials should demonstrate high levels of safety and medical capacity...

  • Worldwide Clinial Trials Drug Development Solutions.  // Applied Clinical Trials;Dec2010, Vol. 19 Issue 12, p138 

    The article presents the corporate profile of Worldwide Clinical Trials Drug Development Solutions, a company which offers Phase I-IV clinical research services and bioanalytical sciences based in Austin, Texas. The company commits to cost-effective and highly efficient processes and methods. It...

  • Problems in Statistical Analysis of Attrition in Randomized Controlled Clinical Trials of Antidepressant for Geriatric Depression. Moonseong Heo; Leon, Andrew C.; Meyers, Barnett S.; Alexopoulos, Georges A. // Current Psychiatry Reviews;2007, Vol. 3 Issue 3, p178 

    Attrition from clinical trials is unavoidable in geriatric psychiatry and beyond. It results in incomplete data and consequently imposes three fundamental challenges: greater bias, reduced power, and less generalizability. In an effort to assess the extent of attrition and the relevance of...

  • Researchers call animal models biased in stroke assessments. Moran, Nuala // Diagnostics & Imaging Week;9/27/2007, Vol. 10 Issue 39, p1 

    The article reports on the claim of an international group of researchers that a widespread failure to control bias in animal tests is the cause of the unprecedented attrition rates that are seen when treatments for stroke are progressed into clinical trials. Leading an international research...

  • time for person centered research in neuroscience: users driving the change. Price, Amy; Chatterjee, Pranab; Biswas, Rakesh // Annals of Neurosciences;Apr2014, Vol. 21 Issue 2, p37 

    The article discusses the person-centered research in neuroscience with clinical trials system showing a decline in enrolment and compliance in unreported serious adverse events, attrition and clinical trials contamination. It presents a diagram showing the process for research in knee...

  • The long road of biopharmaceutical drug development: from inception to marketing. Mundae, M. K.; ÖstÖr, A. J. K. // QJM: An International Journal of Medicine;Jan2010, Vol. 103 Issue 1, p3 

    The development of therapeutics is costly, time-consuming and has high attrition rates. Biopharmaceutical medications differ from traditional agents in their discovery, design, structure and formulation. Prior to marketing a drug must show efficacy and acceptable toxicity in both preclinical and...

  • Missing data in clinical trials: Pitfalls and remedies. Kaushal, Sandeep // International Journal of Applied & Basic Medical Research;2014 Supplement, pS6 

    The author comments on the problems and solutions in dealing with missing data in clinical trials. The author discusses the importance of attrition and missing data after enrollment of subjects in the clinical trial, reasons behind the missing of data, the three types of the missing data, and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics